Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1621 AL 1635

Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD

van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, Miyasaki JM, Zurowski M, Lang AE, Strafella AP.

Neurology. 2010 Nov 9;75(19):1711-6. doi: 10.1212/WNL.0b013e3181fc27fa. Epub 2010 Oct 6.

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR; Global PD Gene Expression (GPEX) Consortium.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059.

[From yeast to neurodegenerative diseases: ten years of exploration of mitochondrial dynamic disorders]

Lenaers G, Amati-Bonneau P, Delettre C, Chevrollier A, Verny C, Miléa D, Procaccio V, Bonneau D, Hamel C, Reynier P.

Med Sci (Paris). 2010 Oct;26(10):836-41. doi: 10.1051/medsci/20102610836.

Mild cognitive impairment is associated with mild parkinsonian signs in a door-to-door study

Israeli-Korn SD, Massarwa M, Schechtman E, Strugatsky R, Avni S, Farrer LA, Friedland RP, Inzelberg R.

J Alzheimers Dis. 2010;22(3):1005-13. doi: 10.3233/JAD-2010-101230.

[Dopaminergic neuroprotection and reconstruction of neural network tiara]

Kitamura Y.

Yakugaku Zasshi. 2010 Oct;130(10):1263-72. doi: 10.1248/yakushi.130.1263.

Scales to assess sleep impairment in Parkinson's disease: critique and recommendations

Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG.

Mov Disord. 2010 Dec 15;25(16):2704-16. doi: 10.1002/mds.23190.

Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease

Perez-Lloret S, Rascol O.

CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000.

An association between immunosenescence and CD4(+)CD25(+) regulatory T cells: a systematic review

Wang L, Xie Y, Zhu LJ, Chang TT, Mao YQ, Li J.

Biomed Environ Sci. 2010 Aug;23(4):327-32. doi: 10.1016/S0895-3988(10)60072-4.

In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery

De Vry J, Martínez-Martínez P, Losen M, Temel Y, Steckler T, Steinbusch HW, De Baets MH, Prickaerts J.

Prog Neurobiol. 2010 Nov;92(3):227-44. doi: 10.1016/j.pneurobio.2010.10.001. Epub 2010 Oct 16.

The genetics of Parkinson disease

Bekris LM, Mata IF, Zabetian CP.

J Geriatr Psychiatry Neurol. 2010 Dec;23(4):228-42. doi: 10.1177/0891988710383572. Epub 2010 Oct 11.

Shortness of breath in a Parkinson's disease patient

Di Lazzaro V, Pilato F, Granone P, Sestito A, Pirronti T.

Mov Disord. 2010 Dec 15;25(16):2897-8. doi: 10.1002/mds.23367.

Neurochemistry changes associated with mutations in familial Parkinson's disease

Siddique MM, Tan EK.

Curr Med Chem. 2010;17(35):4378-91. doi: 10.2174/092986710793361270.

Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists

Beinat C, Banister S, Moussa I, Reynolds AJ, McErlean CS, Kassiou M.

Curr Med Chem. 2010;17(34):4166-90. doi: 10.2174/092986710793348572.

Performance of Greek demented and nondemented subjects on the Greek version of the Mattis Dementia Rating Scale. A validation study

Katsarou Z, Bostantjopoulou S, Zikouli A, Kazazi E, Kafantari A, Tsipropoulou V, Kourtesi G, Peitsidou E.

Int J Neurosci. 2010 Nov;120(11):724-30. doi: 10.3109/00207454.2010.518779.

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics

Kalia SK, Kalia LV, McLean PJ.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):741-53. doi: 10.2174/187152710793237386.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias